+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Analysis of cathepsin D in human breast cancer: usefulness of the processed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients



Analysis of cathepsin D in human breast cancer: usefulness of the processed 31 kDa active form of the enzyme as a prognostic indicator in node-negative and node-positive patients



Breast Cancer Research and Treatment 60(2): 173-179



The relative amounts of the precursor (52 kDa) and processed (31,27 kDa) forms of cathepsin D have been analyzed by Western blotting in biopsied breast tissue cytosols from 134 lesions from invasive breast cancer patients, 24 lesions from patients with ductal carcinoma in situ (DCIS), 227 lesions from benign breast disease patients, and 28 lesions from normal control subjects. The mean relative percentage amount of the 31 kDa form was significantly increased (p < 0.001) in the invasive breast cancer group compared to the other three groups. In addition, the mean relative percentage amount of the 31 kDa form was significantly increased (p < 0.05) in node-positive compared to node-negative breast cancer patients. In the benign breast disease group, patients with proliferative-type disease had a significantly increased (p = 0.02) mean relative percentage amount of the 31 kDa form of cathepsin D compared to patients with nonproliferative-type disease. Invasive breast cancer patients were followed for up to 75 months to determine if the relative percentage amount of the 31 kDa form of cathepsin D was predictive of disease-free and overall survival. Although the amount of the 31 kDa form was not predictive of disease-free survival, patients in the 'high' 31 kDa group (> 18%) were significantly (p < 0.05) more likely to die than patients in the 'low' 31 kDa group (< or = 18%). The 12 patients who died were all node-positive and in the high 31 kDa group. It thus appears that the relative amount of the processed, active 31 kDa form of cathepsin D is a useful prognostic indicator, at least in node-positive breast cancer patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 045244281

Download citation: RISBibTeXText

PMID: 10845280


Related references

Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Research 52(19): 5198-5203, 1992

Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators. Clinical Cancer Research 6(2): 578-584, 2000

Assessment of sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer in two subgroups: Initially node negative and node positive converted to node negative - A systemic review and meta-analysis. Journal of Research in Medical Sciences 24: 18, 2019

Prognostic significance of the immunohistochemical reaction to human milk fat globule antibodies in node-negative and node-positive breast cancer. Breast Cancer Research and Treatment 21(3): 193-199, 1992

Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients. International Journal of Oncology 12(5): 1117-1125, 1998

Preoperative Prediction of Node-Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node-Negative or Node-Positive Breast Cancer. Annals of Surgical Oncology 24(9): 2518-2525, 2017

Differential prognostic role of cytokeratin-positive bone marrow and lymph node micrometastasis on survival of node-negative breast cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting (41): 390-391, 2000

Cathepsin d and other markers as prognostic indicators for node negative breast cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 32: 164, 1991

Prognostic variables in node-negative and node-positive breast cancer - Introduction. Breast Cancer Research and Treatment 51(3): 193-194, 1998

Prognostic variables in node-negative and node-positive breast cancer. Breast Cancer Research and Treatment 52(1-3): 321-331, 1998

The morphometric prognostic index is the strongest prognosticator in premenopausal lymph node-negative and lymph node-positive breast cancer patients. Human Pathology 22(4): 326-330, 1991

The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer. Oncotarget 8(27): 44870-44880, 2017

Shc proteins are strong, independent prognostic markers for both node-negative and node-positive primary breast cancer. Cancer Research 63(20): 6772-6783, 2003

TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncologica 39(3): 327-333, 2000

Re-evaluating the prognostic validity of the negative to positive lymph node ratio in node-positive gastric cancer patients. Surgery 161(6): 1588-1596, 2017